Emerging clinical evidence shows that TRIM59 were frequently up-regulated in tumor tissues compared with noncancerous tissues from breast and gastric tumors, where increased levels were correlated with advanced clinical stages and reduced survival among cancer patients [16, 31]. This evidence concerns the gene TRIM59 and gastric neoplasm.